Transdermal delivery systems for delivery of Alzheimers pharmaceuticals, particularly donepezil, over one to seven days are disclosed which deliver the free-base form of the Alzheimers pharmaceutical at a skin permeation rate such that blood levels of the Alzheimers pharmaceuticals are comparable to the approved oral dosage forms.